{"protocolSection":{"identificationModule":{"nctId":"NCT04887948","orgStudyIdInfo":{"id":"B7471026"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2","officialTitle":"A PHASE 3, RANDOMIZED, DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162b2 IN ADULTS 65 YEARS OF AGE AND OLDER"},"statusModule":{"statusVerifiedDate":"2022-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-05-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-12-08","type":"ACTUAL"},"completionDateStruct":{"date":"2021-12-08","type":"ACTUAL"},"studyFirstSubmitDate":"2021-05-10","studyFirstSubmitQcDate":"2021-05-10","studyFirstPostDateStruct":{"date":"2021-05-14","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-10-07","resultsFirstSubmitQcDate":"2022-11-17","resultsFirstPostDateStruct":{"date":"2022-12-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-11-17","lastUpdatePostDateStruct":{"date":"2022-12-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone"},"conditionsModule":{"conditions":["Pneumococcal Disease","COVID-19","SARS-CoV-2 Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","maskingDescription":"Triple","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":570,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Coadministration Group","type":"EXPERIMENTAL","description":"Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.","interventionNames":["Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)","Biological: BNT162b2"]},{"label":"20vPnC-only Group","type":"ACTIVE_COMPARATOR","description":"Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.","interventionNames":["Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)","Other: Saline"]},{"label":"BNT162b2-only Group","type":"ACTIVE_COMPARATOR","description":"Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.","interventionNames":["Biological: BNT162b2","Other: Saline"]}],"interventions":[{"type":"BIOLOGICAL","name":"20-valent pneumococcal conjugate vaccine (20vPnC)","description":"20-valent pneumococcal conjugate vaccine (20vPnC)","armGroupLabels":["20vPnC-only Group","Coadministration Group"]},{"type":"BIOLOGICAL","name":"BNT162b2","description":"RNA-based SARS-CoV-2 vaccine (BNT162b2)","armGroupLabels":["BNT162b2-only Group","Coadministration Group"]},{"type":"OTHER","name":"Saline","description":"Normal saline for injection","armGroupLabels":["20vPnC-only Group","BNT162b2-only Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Local Reactions at Each Injection Site Within 10 Days After Vaccination","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\\>) 2.0 to 5.0 cm, moderate: \\>5.0 to 10.0 cm and severe: \\>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at each injection site within 10 days after vaccination and the associated 2-sided 95% confidence interval (CI) based on the Clopper and Pearson method was presented.","timeFrame":"Within 10 days after vaccination"},{"measure":"Percentage of Participants With Systemic Events Within 7 Days After Vaccination","description":"Systemic events including fever, fatigue, headache, chills, muscle pain and joint pain were recorded by participants using an e-diary. Fever was defined as temperature \\>=38.0 degree Celsius (C) and categorized as \\>=38.0 to 38.4 degree C, \\>38.4 to 38.9 degree C, \\>38.9 to 40.0 degree C and \\>40.0 degree C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Percentage of participants with systemic events within 7 days after vaccination and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.","timeFrame":"Within 7 days after vaccination"},{"measure":"Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","timeFrame":"From day of vaccination (Day 1) up to 1 month after vaccination"},{"measure":"Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination","description":"A SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event. Percentage of participants with SAEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.","timeFrame":"From day of vaccination (Day 1) up to 6 months after vaccination"}],"secondaryOutcomes":[{"measure":"Geometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) at 1 Month After Vaccination With 20vPnC","description":"OPA titers were measured from serum samples for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F,8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the OPA titers and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and 20vPnC only group (20vPnC + saline) as specified in protocol.","timeFrame":"1 month after vaccination with 20vPnC"},{"measure":"Geometric Mean Concentration (GMC) of Full-Length S-Binding Immunoglobulin G (IgG) Levels at 1 Month After Vaccination With BNT162b2","description":"IgG levels were measured in serum samples using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length S-binding assay. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in protocol.","timeFrame":"1 month after vaccination with BNT162b2"},{"measure":"Geometric Mean Fold Rise (GMFR) of Full-Length S-Binding IgG Levels From Before Vaccination to 1 Month After Vaccination With BNT162b2","description":"The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from before to approximately 1 month after vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in the protocol.","timeFrame":"Before vaccination to 1 month after vaccination with BNT162b2"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female participants ≥65 years of age at the time of consent\n* Participating or participated in Study C4591001, received 2 doses of 30 µg BNT162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of BNT162b2\n* Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease\n* Adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study\n\nExclusion Criteria:\n\n* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)\n* Serious chronic disorder that in the investigator's opinion would make the participant inappropriate for entry into the study\n* Previous clinical or microbiological diagnosis of COVID-19\n* Previous vaccination with any investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation\n* Previous vaccination with any coronavirus vaccine, other than those received in Study C4591001\n* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Anaheim Clinical Trials, LLC","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"Diablo Clinical Research, Inc.","city":"Walnut Creek","state":"California","zip":"94598","country":"United States","geoPoint":{"lat":37.90631,"lon":-122.06496}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Indago Research & Health Center, Inc","city":"Hialeah","state":"Florida","zip":"33012","country":"United States","geoPoint":{"lat":25.8576,"lon":-80.27811}},{"facility":"Research Centers of America ( Hollywood )","city":"Hollywood","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"Acevedo Clinical Research Associates","city":"Miami","state":"Florida","zip":"33142","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Clinical Neuroscience Solutions","city":"Orlando","state":"Florida","zip":"32801","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Clinical Research Atlanta","city":"Stockbridge","state":"Georgia","zip":"30281","country":"United States","geoPoint":{"lat":33.54428,"lon":-84.23381}},{"facility":"East-West Medical Research Institute","city":"Honolulu","state":"Hawaii","zip":"96814","country":"United States","geoPoint":{"lat":21.30694,"lon":-157.85833}},{"facility":"Solaris Clinical Research","city":"Meridian","state":"Idaho","zip":"83646","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Newton","state":"Kansas","zip":"67114","country":"United States","geoPoint":{"lat":38.04668,"lon":-97.34504}},{"facility":"Clinical Research Professionals","city":"Chesterfield","state":"Missouri","zip":"63005","country":"United States","geoPoint":{"lat":38.66311,"lon":-90.57707}},{"facility":"Sundance Clinical Research","city":"St Louis","state":"Missouri","zip":"63141","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Meridian Clinical Research, LLC","city":"Omaha","state":"Nebraska","zip":"68134","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Meridian Clinical Research, LLC","city":"Endwell","state":"New York","zip":"13760","country":"United States","geoPoint":{"lat":42.11285,"lon":-76.02103}},{"facility":"Accellacare - Wilmington","city":"Wilmington","state":"North Carolina","zip":"28401","country":"United States","geoPoint":{"lat":34.23556,"lon":-77.94604}},{"facility":"Aventiv Research Inc","city":"Columbus","state":"Ohio","zip":"43213","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Alliance for Multispecialty Research, LLC","city":"Knoxville","state":"Tennessee","zip":"37909","country":"United States","geoPoint":{"lat":35.96064,"lon":-83.92074}},{"facility":"Clinical Neuroscience Solutions, Inc. dba CNS Healthcare","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Benchmark Research","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"IMA Clinical Research San Antonio","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"DM Clinical Research","city":"Tomball","state":"Texas","zip":"77375","country":"United States","geoPoint":{"lat":30.09716,"lon":-95.61605}},{"facility":"Martin Diagnostic Clinic","city":"Tomball","state":"Texas","zip":"77375","country":"United States","geoPoint":{"lat":30.09716,"lon":-95.61605}},{"facility":"Martins Diagnostic Clinic","city":"Tomball","state":"Texas","zip":"77375","country":"United States","geoPoint":{"lat":30.09716,"lon":-95.61605}},{"facility":"J. Lewis Research, Inc. / Foothill Family Clinic","city":"Salt Lake City","state":"Utah","zip":"84109","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"J. Lewis Research, Inc. / Foothill Family Clinic South","city":"Salt Lake City","state":"Utah","zip":"84121","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Wenatchee Valley Hospital","city":"Wenatchee","state":"Washington","zip":"98801","country":"United States","geoPoint":{"lat":47.42346,"lon":-120.31035}}]},"referencesModule":{"references":[{"pmid":"37244809","type":"DERIVED","citation":"Fitz-Patrick D, Young M, Yacisin K, McElwee K, Belanger T, Belanger K, Peng Y, Lee DY, Gruber WC, Scott DA, Watson W. Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults >/=65 years old. Vaccine. 2023 Jun 23;41(28):4190-4198. doi: 10.1016/j.vaccine.2023.05.002. Epub 2023 May 8."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://pmiform.com/clinical-trial-info-request?StudyID=B7471026"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\\_trials/trial\\_data\\_and\\_results/data\\_requests.","url":"https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 570 participants were enrolled in the study and randomized to a study treatment.","recruitmentDetails":"Eligible participants who received 2 doses of ribonucleic acid (RNA)-based COVID-19 vaccine (BNT162b2) at least 6 months previously in study C4591001 (NCT04368728) were stratified by prior pneumococcal vaccine status (no previous pneumococcal vaccine \\[naïve\\] or receipt of at least 1 dose of a pneumococcal vaccine \\[experienced\\]) and randomized to 1 of the 3 vaccine groups in this study.","groups":[{"id":"FG000","title":"Coadministration Group: 20vPnC+BNT162b2","description":"On Day 1, participants were randomized to receive a single dose of 0.5 milliliter (mL) 20-valent pneumococcal conjugate vaccine (20vPnC) intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"FG001","title":"20vPnC Only Group: 20vPnC+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL saline intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"FG002","title":"BNT162b2 Only Group: BNT162b2+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL saline intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"190"},{"groupId":"FG001","numSubjects":"191"},{"groupId":"FG002","numSubjects":"189"}]},{"type":"Vaccinated","achievements":[{"groupId":"FG000","numSubjects":"187"},{"groupId":"FG001","numSubjects":"187"},{"groupId":"FG002","numSubjects":"185"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"184"},{"groupId":"FG001","numSubjects":"177"},{"groupId":"FG002","numSubjects":"182"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"No longer met eligibility criteria","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention and had safety follow-up after vaccination.","groups":[{"id":"BG000","title":"Coadministration Group: 20vPnC+BNT162b2","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"BG001","title":"20vPnC Only Group: 20vPnC+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL saline intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"BG002","title":"BNT162b2 Only Group: BNT162b2+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL saline intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"187"},{"groupId":"BG001","value":"187"},{"groupId":"BG002","value":"185"},{"groupId":"BG003","value":"559"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71.0","spread":"4.22"},{"groupId":"BG001","value":"71.8","spread":"4.94"},{"groupId":"BG002","value":"71.8","spread":"4.95"},{"groupId":"BG003","value":"71.5","spread":"4.72"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"77"},{"groupId":"BG003","value":"241"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"112"},{"groupId":"BG002","value":"108"},{"groupId":"BG003","value":"318"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"79"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"159"},{"groupId":"BG001","value":"161"},{"groupId":"BG002","value":"160"},{"groupId":"BG003","value":"480"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"24"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"25"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"164"},{"groupId":"BG001","value":"172"},{"groupId":"BG002","value":"165"},{"groupId":"BG003","value":"501"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"6"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Local Reactions at Each Injection Site Within 10 Days After Vaccination","description":"Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\\>) 2.0 to 5.0 cm, moderate: \\>5.0 to 10.0 cm and severe: \\>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at each injection site within 10 days after vaccination and the associated 2-sided 95% confidence interval (CI) based on the Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention and had safety follow-up after vaccination. Here, \"Overall Number of Participants Analyzed\" signifies number of participants with any e-diary data reported after vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 10 days after vaccination","groups":[{"id":"OG000","title":"Coadministration Group (20vPnC+BNT162b2): 20vPnC Vaccination Site","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG001","title":"Coadministration Group (20vPnC+BNT162b2): BNT162b2 Vaccination Site","description":"On Day 1, participants were randomized to receive a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG002","title":"20vPnC Only Group (20vPnC+Saline): 20vPnC Vaccination Site","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG003","title":"20vPnC Only Group (20vPnC+Saline): Saline Vaccination Site","description":"On Day 1, participants were randomized to receive a single dose of 0.3 mL saline intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG004","title":"BNT162b2 Only Group (BNT162b2+Saline): BNT162b2 Vaccination Site","description":"On Day 1, participants were randomized to receive a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG005","title":"BNT162b2 Only Group (BNT162b2+Saline): Saline Vaccination Site","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL saline intramuscularly into the right deltoid. Participants were followed up for 6 months after vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"185"},{"groupId":"OG002","value":"186"},{"groupId":"OG003","value":"186"},{"groupId":"OG004","value":"185"},{"groupId":"OG005","value":"185"}]}],"classes":[{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"5.0","upperLimit":"13.7"},{"groupId":"OG001","value":"9.7","lowerLimit":"5.9","upperLimit":"14.9"},{"groupId":"OG002","value":"8.1","lowerLimit":"4.6","upperLimit":"13.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG004","value":"9.7","lowerLimit":"5.9","upperLimit":"14.9"},{"groupId":"OG005","value":"2.7","lowerLimit":"0.9","upperLimit":"6.2"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.9","lowerLimit":"3.0","upperLimit":"10.4"},{"groupId":"OG001","value":"5.9","lowerLimit":"3.0","upperLimit":"10.4"},{"groupId":"OG002","value":"4.3","lowerLimit":"1.9","upperLimit":"8.3"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG004","value":"6.5","lowerLimit":"3.4","upperLimit":"11.1"},{"groupId":"OG005","value":"2.2","lowerLimit":"0.6","upperLimit":"5.4"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"0.9","upperLimit":"6.2"},{"groupId":"OG001","value":"3.2","lowerLimit":"1.2","upperLimit":"6.9"},{"groupId":"OG002","value":"3.2","lowerLimit":"1.2","upperLimit":"6.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG004","value":"2.7","lowerLimit":"0.9","upperLimit":"6.2"},{"groupId":"OG005","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"},{"groupId":"OG002","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG004","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"},{"groupId":"OG005","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"4.6","upperLimit":"13.0"},{"groupId":"OG001","value":"9.7","lowerLimit":"5.9","upperLimit":"14.9"},{"groupId":"OG002","value":"8.6","lowerLimit":"5.0","upperLimit":"13.6"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG004","value":"11.4","lowerLimit":"7.2","upperLimit":"16.8"},{"groupId":"OG005","value":"1.1","lowerLimit":"0.1","upperLimit":"3.9"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"2.6","upperLimit":"9.7"},{"groupId":"OG001","value":"5.9","lowerLimit":"3.0","upperLimit":"10.4"},{"groupId":"OG002","value":"5.4","lowerLimit":"2.6","upperLimit":"9.7"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG004","value":"6.5","lowerLimit":"3.4","upperLimit":"11.1"},{"groupId":"OG005","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","lowerLimit":"0.9","upperLimit":"6.2"},{"groupId":"OG001","value":"3.8","lowerLimit":"1.5","upperLimit":"7.6"},{"groupId":"OG002","value":"3.2","lowerLimit":"1.2","upperLimit":"6.9"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG004","value":"4.9","lowerLimit":"2.2","upperLimit":"9.0"},{"groupId":"OG005","value":"1.1","lowerLimit":"0.1","upperLimit":"3.9"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG005","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Pain at injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"73.0","lowerLimit":"66.0","upperLimit":"79.2"},{"groupId":"OG001","value":"72.4","lowerLimit":"65.4","upperLimit":"78.7"},{"groupId":"OG002","value":"60.2","lowerLimit":"52.8","upperLimit":"67.3"},{"groupId":"OG003","value":"9.7","lowerLimit":"5.8","upperLimit":"14.9"},{"groupId":"OG004","value":"67.6","lowerLimit":"60.3","upperLimit":"74.3"},{"groupId":"OG005","value":"16.8","lowerLimit":"11.7","upperLimit":"22.9"}]}]},{"title":"Pain at injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"55.1","lowerLimit":"47.7","upperLimit":"62.4"},{"groupId":"OG001","value":"56.8","lowerLimit":"49.3","upperLimit":"64.0"},{"groupId":"OG002","value":"52.2","lowerLimit":"44.7","upperLimit":"59.5"},{"groupId":"OG003","value":"9.7","lowerLimit":"5.8","upperLimit":"14.9"},{"groupId":"OG004","value":"50.3","lowerLimit":"42.8","upperLimit":"57.7"},{"groupId":"OG005","value":"16.2","lowerLimit":"11.2","upperLimit":"22.3"}]}]},{"title":"Pain at injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"17.8","lowerLimit":"12.6","upperLimit":"24.1"},{"groupId":"OG001","value":"15.7","lowerLimit":"10.8","upperLimit":"21.7"},{"groupId":"OG002","value":"7.0","lowerLimit":"3.8","upperLimit":"11.7"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG004","value":"17.3","lowerLimit":"12.1","upperLimit":"23.5"},{"groupId":"OG005","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"}]}]},{"title":"Pain at injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG002","value":"1.1","lowerLimit":"0.1","upperLimit":"3.8"},{"groupId":"OG003","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG004","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG005","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Systemic Events Within 7 Days After Vaccination","description":"Systemic events including fever, fatigue, headache, chills, muscle pain and joint pain were recorded by participants using an e-diary. Fever was defined as temperature \\>=38.0 degree Celsius (C) and categorized as \\>=38.0 to 38.4 degree C, \\>38.4 to 38.9 degree C, \\>38.9 to 40.0 degree C and \\>40.0 degree C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Percentage of participants with systemic events within 7 days after vaccination and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention and had safety follow-up after vaccination. Here, \"Overall Number of Participants Analyzed\" (N) signifies number of participants with any e-diary data reported after vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after vaccination","groups":[{"id":"OG000","title":"Coadministration Group: 20vPnC+BNT162b2","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG001","title":"20vPnC Only Group: 20vPnC+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL saline intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG002","title":"BNT162b2 Only Group: BNT162b2+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL saline intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"185"}]}],"classes":[{"title":"Fever: >=38.0 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"13.0","lowerLimit":"8.5","upperLimit":"18.7"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.1","upperLimit":"3.8"},{"groupId":"OG002","value":"8.6","lowerLimit":"5.0","upperLimit":"13.7"}]}]},{"title":"Fever: >=38.0 degree C to 38.4 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"3.8","upperLimit":"11.7"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"},{"groupId":"OG002","value":"2.7","lowerLimit":"0.9","upperLimit":"6.2"}]}]},{"title":"Fever: >38.4 degree C to 38.9 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"2.6","upperLimit":"9.7"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"},{"groupId":"OG002","value":"4.9","lowerLimit":"2.2","upperLimit":"9.0"}]}]},{"title":"Fever: >38.9 degree C to 40.0 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG002","value":"1.1","lowerLimit":"0.1","upperLimit":"3.9"}]}]},{"title":"Fever: >40.0 degree C","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"}]}]},{"title":"Fatigue: Any","categories":[{"measurements":[{"groupId":"OG000","value":"54.1","lowerLimit":"46.6","upperLimit":"61.4"},{"groupId":"OG001","value":"36.0","lowerLimit":"29.1","upperLimit":"43.4"},{"groupId":"OG002","value":"54.6","lowerLimit":"47.1","upperLimit":"61.9"}]}]},{"title":"Fatigue: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"17.8","lowerLimit":"12.6","upperLimit":"24.1"},{"groupId":"OG001","value":"23.7","lowerLimit":"17.7","upperLimit":"30.4"},{"groupId":"OG002","value":"27.0","lowerLimit":"20.8","upperLimit":"34.0"}]}]},{"title":"Fatigue: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"33.0","lowerLimit":"26.3","upperLimit":"40.3"},{"groupId":"OG001","value":"12.4","lowerLimit":"8.0","upperLimit":"18.0"},{"groupId":"OG002","value":"24.9","lowerLimit":"18.8","upperLimit":"31.7"}]}]},{"title":"Fatigue: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"1.2","upperLimit":"6.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG002","value":"2.7","lowerLimit":"0.9","upperLimit":"6.2"}]}]},{"title":"Headache: Any","categories":[{"measurements":[{"groupId":"OG000","value":"30.3","lowerLimit":"23.7","upperLimit":"37.4"},{"groupId":"OG001","value":"17.2","lowerLimit":"12.1","upperLimit":"23.4"},{"groupId":"OG002","value":"33.0","lowerLimit":"26.3","upperLimit":"40.3"}]}]},{"title":"Headache: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"17.8","lowerLimit":"12.6","upperLimit":"24.1"},{"groupId":"OG001","value":"14.5","lowerLimit":"9.8","upperLimit":"20.4"},{"groupId":"OG002","value":"24.9","lowerLimit":"18.8","upperLimit":"31.7"}]}]},{"title":"Headache: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"11.9","lowerLimit":"7.6","upperLimit":"17.4"},{"groupId":"OG001","value":"2.7","lowerLimit":"0.9","upperLimit":"6.2"},{"groupId":"OG002","value":"7.6","lowerLimit":"4.2","upperLimit":"12.4"}]}]},{"title":"Headache: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG002","value":"0.5","lowerLimit":"0.0","upperLimit":"3.0"}]}]},{"title":"Chills: Any","categories":[{"measurements":[{"groupId":"OG000","value":"26.5","lowerLimit":"20.3","upperLimit":"33.5"},{"groupId":"OG001","value":"7.0","lowerLimit":"3.8","upperLimit":"11.7"},{"groupId":"OG002","value":"22.2","lowerLimit":"16.4","upperLimit":"28.8"}]}]},{"title":"Chills: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"18.4","lowerLimit":"13.1","upperLimit":"24.7"},{"groupId":"OG001","value":"5.9","lowerLimit":"3.0","upperLimit":"10.3"},{"groupId":"OG002","value":"12.4","lowerLimit":"8.0","upperLimit":"18.1"}]}]},{"title":"Chills: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"3.4","upperLimit":"11.1"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.1","upperLimit":"3.8"},{"groupId":"OG002","value":"7.6","lowerLimit":"4.2","upperLimit":"12.4"}]}]},{"title":"Chills: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"0.3","upperLimit":"4.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG002","value":"2.2","lowerLimit":"0.6","upperLimit":"5.4"}]}]},{"title":"Muscle pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"32.4","lowerLimit":"25.7","upperLimit":"39.7"},{"groupId":"OG001","value":"14.5","lowerLimit":"9.8","upperLimit":"20.4"},{"groupId":"OG002","value":"31.9","lowerLimit":"25.2","upperLimit":"39.1"}]}]},{"title":"Muscle pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"17.3","lowerLimit":"12.1","upperLimit":"23.5"},{"groupId":"OG001","value":"10.2","lowerLimit":"6.3","upperLimit":"15.5"},{"groupId":"OG002","value":"15.7","lowerLimit":"10.8","upperLimit":"21.7"}]}]},{"title":"Muscle pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"14.1","lowerLimit":"9.4","upperLimit":"19.9"},{"groupId":"OG001","value":"4.3","lowerLimit":"1.9","upperLimit":"8.3"},{"groupId":"OG002","value":"15.1","lowerLimit":"10.3","upperLimit":"21.1"}]}]},{"title":"Muscle pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.1","upperLimit":"3.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG002","value":"1.1","lowerLimit":"0.1","upperLimit":"3.9"}]}]},{"title":"Joint pain: Any","categories":[{"measurements":[{"groupId":"OG000","value":"26.5","lowerLimit":"20.3","upperLimit":"33.5"},{"groupId":"OG001","value":"9.1","lowerLimit":"5.4","upperLimit":"14.2"},{"groupId":"OG002","value":"24.9","lowerLimit":"18.8","upperLimit":"31.7"}]}]},{"title":"Joint pain: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"15.1","lowerLimit":"10.3","upperLimit":"21.1"},{"groupId":"OG001","value":"5.4","lowerLimit":"2.6","upperLimit":"9.7"},{"groupId":"OG002","value":"15.1","lowerLimit":"10.3","upperLimit":"21.1"}]}]},{"title":"Joint pain: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"11.4","lowerLimit":"7.2","upperLimit":"16.8"},{"groupId":"OG001","value":"3.8","lowerLimit":"1.5","upperLimit":"7.6"},{"groupId":"OG002","value":"9.7","lowerLimit":"5.9","upperLimit":"14.9"}]}]},{"title":"Joint pain: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"},{"groupId":"OG002","value":"0.0","lowerLimit":"0.0","upperLimit":"2.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination","description":"An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention and had safety follow-up after vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From day of vaccination (Day 1) up to 1 month after vaccination","groups":[{"id":"OG000","title":"Coadministration Group: 20vPnC+BNT162b2","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG001","title":"20vPnC Only Group: 20vPnC+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL saline intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG002","title":"BNT162b2 Only Group: BNT162b2+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL saline intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"187"},{"groupId":"OG002","value":"185"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"2.6","upperLimit":"9.6"},{"groupId":"OG001","value":"4.3","lowerLimit":"1.9","upperLimit":"8.3"},{"groupId":"OG002","value":"6.5","lowerLimit":"3.4","upperLimit":"11.1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination","description":"A SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event. Percentage of participants with SAEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.","populationDescription":"Safety population included all participants who received at least 1 dose of the study intervention and had safety follow-up after vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From day of vaccination (Day 1) up to 6 months after vaccination","groups":[{"id":"OG000","title":"Coadministration Group: 20vPnC+BNT162b2","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG001","title":"20vPnC Only Group: 20vPnC+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL saline intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG002","title":"BNT162b2 Only Group: BNT162b2+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL saline intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"187"},{"groupId":"OG002","value":"185"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.0","upperLimit":"2.9"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.1","upperLimit":"3.8"},{"groupId":"OG002","value":"2.7","lowerLimit":"0.9","upperLimit":"6.2"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) at 1 Month After Vaccination With 20vPnC","description":"OPA titers were measured from serum samples for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F,8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the OPA titers and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and 20vPnC only group (20vPnC + saline) as specified in protocol.","populationDescription":"Evaluable immunogenicity population (EIP): all randomized participants who received assigned vaccination; had at least 1 valid immunogenicity result from the blood sample collected within 20 to 49 days after vaccination at Day 1; had no other major protocol deviations as determined by clinician. Here, \"Number Analyzed\" signifies participants with valid OPA titers for the specified serotype.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"1 month after vaccination with 20vPnC","groups":[{"id":"OG000","title":"Coadministration Group: 20vPnC+BNT162b2","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG001","title":"20vPnC Only Group: 20vPnC+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL saline intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"184"},{"groupId":"OG001","value":"182"}]}],"classes":[{"title":"Serotype 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"142","lowerLimit":"116","upperLimit":"176"},{"groupId":"OG001","value":"131","lowerLimit":"106","upperLimit":"162"}]}]},{"title":"Serotype 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49","lowerLimit":"42","upperLimit":"56"},{"groupId":"OG001","value":"52","lowerLimit":"44","upperLimit":"61"}]}]},{"title":"Serotype 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"609","lowerLimit":"484","upperLimit":"766"},{"groupId":"OG001","value":"573","lowerLimit":"447","upperLimit":"734"}]}]},{"title":"Serotype 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81","lowerLimit":"65","upperLimit":"100"},{"groupId":"OG001","value":"98","lowerLimit":"80","upperLimit":"120"}]}]},{"title":"Serotype 6A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"181"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1377","lowerLimit":"1058","upperLimit":"1792"},{"groupId":"OG001","value":"1317","lowerLimit":"1042","upperLimit":"1665"}]}]},{"title":"Serotype 6B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1449","lowerLimit":"1153","upperLimit":"1821"},{"groupId":"OG001","value":"1478","lowerLimit":"1207","upperLimit":"1810"}]}]},{"title":"Serotype 7F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"977","lowerLimit":"836","upperLimit":"1142"},{"groupId":"OG001","value":"1102","lowerLimit":"951","upperLimit":"1275"}]}]},{"title":"Serotype 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"299","lowerLimit":"235","upperLimit":"381"},{"groupId":"OG001","value":"344","lowerLimit":"274","upperLimit":"431"}]}]},{"title":"Serotype 9V","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1722","lowerLimit":"1365","upperLimit":"2172"},{"groupId":"OG001","value":"1531","lowerLimit":"1210","upperLimit":"1936"}]}]},{"title":"Serotype 10A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"177"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2252","lowerLimit":"1751","upperLimit":"2898"},{"groupId":"OG001","value":"2644","lowerLimit":"2023","upperLimit":"3456"}]}]},{"title":"Serotype 11A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"165"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1875","lowerLimit":"1414","upperLimit":"2488"},{"groupId":"OG001","value":"1932","lowerLimit":"1445","upperLimit":"2583"}]}]},{"title":"Serotype 12F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"169"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2165","lowerLimit":"1668","upperLimit":"2809"},{"groupId":"OG001","value":"2211","lowerLimit":"1695","upperLimit":"2885"}]}]},{"title":"Serotype 14","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"709","lowerLimit":"572","upperLimit":"879"},{"groupId":"OG001","value":"640","lowerLimit":"528","upperLimit":"775"}]}]},{"title":"Serotype 15B","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1520","lowerLimit":"1092","upperLimit":"2117"},{"groupId":"OG001","value":"1852","lowerLimit":"1377","upperLimit":"2491"}]}]},{"title":"Serotype 18C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"178"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1059","lowerLimit":"869","upperLimit":"1290"},{"groupId":"OG001","value":"846","lowerLimit":"684","upperLimit":"1046"}]}]},{"title":"Serotype 19A","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"179"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"637","lowerLimit":"520","upperLimit":"781"},{"groupId":"OG001","value":"530","lowerLimit":"436","upperLimit":"644"}]}]},{"title":"Serotype 19F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"305","lowerLimit":"242","upperLimit":"383"},{"groupId":"OG001","value":"377","lowerLimit":"299","upperLimit":"476"}]}]},{"title":"Serotype 22F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"167"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5225","lowerLimit":"3931","upperLimit":"6943"},{"groupId":"OG001","value":"4464","lowerLimit":"3354","upperLimit":"5942"}]}]},{"title":"Serotype 23F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"182"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"336","lowerLimit":"251","upperLimit":"450"},{"groupId":"OG001","value":"385","lowerLimit":"283","upperLimit":"524"}]}]},{"title":"Serotype 33F","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"172"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4907","lowerLimit":"3813","upperLimit":"6316"},{"groupId":"OG001","value":"5544","lowerLimit":"4234","upperLimit":"7261"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) of Full-Length S-Binding Immunoglobulin G (IgG) Levels at 1 Month After Vaccination With BNT162b2","description":"IgG levels were measured in serum samples using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length S-binding assay. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in protocol.","populationDescription":"EIP: all randomized participants who received assigned vaccination; had at least 1 valid immunogenicity result from blood sample collected within 20 to 49 days after vaccination at Day 1; had no other major protocol deviations as determined by clinician. Participants with SARS-CoV-2 infection up to 1 month after vaccination (including subclinical infection, ie positive for N-binding antibody) were excluded from analysis. N=participants with valid assay results at specified sampling time point.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Units per milliliter","timeFrame":"1 month after vaccination with BNT162b2","groups":[{"id":"OG000","title":"Coadministration Group: 20vPnC+BNT162b2","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG001","title":"BNT162b2 Only Group: BNT162b2+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL saline intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"177"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29114","lowerLimit":"26120","upperLimit":"32451"},{"groupId":"OG001","value":"26655","lowerLimit":"24003","upperLimit":"29599"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) of Full-Length S-Binding IgG Levels From Before Vaccination to 1 Month After Vaccination With BNT162b2","description":"The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from before to approximately 1 month after vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in the protocol.","populationDescription":"EIP: participants received assigned vaccination; at least 1 valid immunogenicity result from sample collected within 20 to 49 days after Day1 vaccination; no other major protocol deviations determined by clinician. Participants with SARS-CoV-2 infection upto 1 month after vaccination (including subclinical infection, ie positive for N-binding antibody)excluded from analysis. N=participants with valid full-length S-binding IgG from before and 1 month after BNT162b2 booster dose sample collection.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold rise","timeFrame":"Before vaccination to 1 month after vaccination with BNT162b2","groups":[{"id":"OG000","title":"Coadministration Group: 20vPnC+BNT162b2","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."},{"id":"OG001","title":"BNT162b2 Only Group: BNT162b2+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL saline intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"178"},{"groupId":"OG001","value":"177"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","lowerLimit":"30.9","upperLimit":"40.7"},{"groupId":"OG001","value":"39.0","lowerLimit":"33.5","upperLimit":"45.5"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"Systematic assessment: local reactions recorded within 10 days after vaccination, and systemic events recorded within 7 days after vaccination; Non-systematic assessment: SAEs recorded from day of vaccination (Day 1) up to 6 months after vaccination and other AEs recorded from Day 1 up to 1 month after vaccination","description":"Same event may appear as AE and SAE but what is presented are distinct events. Event may be categorized as serious in 1 participant and as non-serious in another participant or 1 participant may have experienced both serious and non-serious event during study.","eventGroups":[{"id":"EG000","title":"Coadministration Group: 20vPnC+BNT162b2","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination.","deathsNumAffected":1,"deathsNumAtRisk":187,"seriousNumAffected":1,"seriousNumAtRisk":187,"otherNumAffected":157,"otherNumAtRisk":187},{"id":"EG001","title":"20vPnC Only Group: 20vPnC+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL 20vPnC intramuscularly into the right deltoid and a single dose of 0.3 mL saline intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination.","deathsNumAffected":0,"deathsNumAtRisk":187,"seriousNumAffected":2,"seriousNumAtRisk":187,"otherNumAffected":137,"otherNumAtRisk":187},{"id":"EG002","title":"BNT162b2 Only Group: BNT162b2+Saline","description":"On Day 1, participants were randomized to receive a single dose of 0.5 mL saline intramuscularly into the right deltoid and a single dose of 0.3 mL booster dose of BNT162b2 intramuscularly into the left deltoid. Participants were followed up for 6 months after vaccination.","deathsNumAffected":0,"deathsNumAtRisk":185,"seriousNumAffected":5,"seriousNumAtRisk":185,"otherNumAffected":149,"otherNumAtRisk":185}],"seriousEvents":[{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":187},{"groupId":"EG001","numAffected":1,"numAtRisk":187},{"groupId":"EG002","numAffected":0,"numAtRisk":185}]},{"term":"Duodenal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":187},{"groupId":"EG001","numAffected":0,"numAtRisk":187},{"groupId":"EG002","numAffected":0,"numAtRisk":185}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":187},{"groupId":"EG001","numAffected":0,"numAtRisk":187},{"groupId":"EG002","numAffected":1,"numAtRisk":185}]},{"term":"Breast cancer stage I","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":187},{"groupId":"EG001","numAffected":0,"numAtRisk":187},{"groupId":"EG002","numAffected":1,"numAtRisk":185}]},{"term":"Glioblastoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":187},{"groupId":"EG001","numAffected":1,"numAtRisk":187},{"groupId":"EG002","numAffected":0,"numAtRisk":185}]},{"term":"Lung adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":187},{"groupId":"EG001","numAffected":0,"numAtRisk":187},{"groupId":"EG002","numAffected":1,"numAtRisk":185}]},{"term":"Metastases to liver","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":187},{"groupId":"EG001","numAffected":0,"numAtRisk":187},{"groupId":"EG002","numAffected":1,"numAtRisk":185}]},{"term":"Small intestine carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":187},{"groupId":"EG001","numAffected":0,"numAtRisk":187},{"groupId":"EG002","numAffected":1,"numAtRisk":185}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":187},{"groupId":"EG001","numAffected":0,"numAtRisk":187},{"groupId":"EG002","numAffected":1,"numAtRisk":185}]}],"otherEvents":[{"term":"Chills (CHILLS)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":187},{"groupId":"EG001","numAffected":13,"numAtRisk":187},{"groupId":"EG002","numAffected":41,"numAtRisk":185}]},{"term":"Fatigue (FATIGUE)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":100,"numAtRisk":187},{"groupId":"EG001","numAffected":67,"numAtRisk":187},{"groupId":"EG002","numAffected":101,"numAtRisk":185}]},{"term":"Injection site erythema (REDNESS)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":187},{"groupId":"EG001","numAffected":15,"numAtRisk":187},{"groupId":"EG002","numAffected":22,"numAtRisk":185}]},{"term":"Injection site pain (PAIN)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":146,"numAtRisk":187},{"groupId":"EG001","numAffected":115,"numAtRisk":187},{"groupId":"EG002","numAffected":133,"numAtRisk":185}]},{"term":"Injection site swelling (SWELLING)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":187},{"groupId":"EG001","numAffected":16,"numAtRisk":187},{"groupId":"EG002","numAffected":21,"numAtRisk":185}]},{"term":"Pyrexia (FEVER)","organSystem":"General disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":187},{"groupId":"EG001","numAffected":2,"numAtRisk":187},{"groupId":"EG002","numAffected":16,"numAtRisk":185}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":187},{"groupId":"EG001","numAffected":0,"numAtRisk":187},{"groupId":"EG002","numAffected":1,"numAtRisk":185}]},{"term":"Arthralgia (JOINT PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":187},{"groupId":"EG001","numAffected":17,"numAtRisk":187},{"groupId":"EG002","numAffected":46,"numAtRisk":185}]},{"term":"Myalgia (MUSCLE PAIN)","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":60,"numAtRisk":187},{"groupId":"EG001","numAffected":27,"numAtRisk":187},{"groupId":"EG002","numAffected":59,"numAtRisk":185}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":187},{"groupId":"EG001","numAffected":0,"numAtRisk":187},{"groupId":"EG002","numAffected":0,"numAtRisk":185}]},{"term":"Headache (HEADACHE)","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v24.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":56,"numAtRisk":187},{"groupId":"EG001","numAffected":32,"numAtRisk":187},{"groupId":"EG002","numAffected":61,"numAtRisk":185}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-04-08","uploadDate":"2022-10-07T15:31","filename":"Prot_000.pdf","size":4855869},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2021-06-30","uploadDate":"2022-10-07T15:31","filename":"SAP_001.pdf","size":3606729}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2022-11-01","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D011008","term":"Pneumococcal Infections"},{"id":"D000086382","term":"COVID-19"}],"ancestors":[{"id":"D013290","term":"Streptococcal Infections"},{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"},{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018352","term":"Coronavirus Infections"},{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000090982","term":"BNT162 Vaccine"},{"id":"D012965","term":"Sodium Chloride"}],"ancestors":[{"id":"D000087503","term":"mRNA Vaccines"},{"id":"D000087504","term":"Nucleic Acid-Based Vaccines"},{"id":"D014614","term":"Vaccines, Synthetic"},{"id":"D011994","term":"Recombinant Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D000086663","term":"COVID-19 Vaccines"},{"id":"D014765","term":"Viral Vaccines"},{"id":"D000941","term":"Antigens"},{"id":"D001685","term":"Biological Factors"},{"id":"D002712","term":"Chlorides"},{"id":"D006851","term":"Hydrochloric Acid"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017670","term":"Sodium Compounds"}]}},"hasResults":true}